Comparative Pharmacology
Head-to-head clinical analysis: CODAMINE versus INVAGESIC.
Peer-Reviewed Evidence
Head-to-head clinical analysis: CODAMINE versus INVAGESIC.
CODAMINE vs INVAGESIC
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Codeine is an opioid agonist that binds to mu-opioid receptors in the CNS, inhibiting ascending pain pathways and altering pain perception. It is a prodrug converted to morphine via CYP2D6.
INVAGESIC is a combination of pregabalin, an alpha2-delta ligand that inhibits presynaptic calcium channels to reduce excitatory neurotransmitter release, and meloxicam, a COX-2 selective NSAID that decreases prostaglandin synthesis via cyclooxygenase inhibition.
Adults: 1-2 tablets (codeine 30 mg + acetaminophen 500 mg per tablet) orally every 4-6 hours as needed for pain; maximum 8 tablets per day.
Adults: 1-2 tablets (325 mg acetaminophen/5 mg hydrocodone) orally every 4-6 hours as needed for pain, not to exceed 12 tablets per day.
None Documented
None Documented
Terminal elimination half-life: 4–6 hours in adults; prolonged to 8–12 hours in renal impairment (CrCl <30 mL/min)
Terminal elimination half-life: 4-6 hours in adults; prolonged to 8-12 hours in elderly or mild renal impairment
Renal: 60% unchanged; Biliary/Fecal: 30% as metabolites; 10% other
Renal: ~70% as unchanged drug; biliary/fecal: ~30% as metabolites
Category C
Category C
Opioid Analgesic Combination
Opioid Analgesic Combination